MIAMI, Oct. 20, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“RCN”). Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
QualTex launches cellular therapy testing services
Lab to support researchers developing new treatments for global healthcare market
SAN ANTONIO, Texas – QualTex Laboratories, a subsidiary of San Antonio-based nonprofit BioBridge Global, has expanded its offerings to include cellular therapy testing services in support of advanced therapeutics clinical developers.
The new service provides a full range of research use only (RUO), current good manufacturing practices (cGMP), and good laboratory practices (GLP) qualified assays to support a variety of cellular therapy industry testing needs. [Read more…]
Steminent Biotherapeutics licenses rights to SCM Lifescience to develop Stemchymal® cell therapy for treating spinocerebellar ataxia (SCA) in South Korea
Taipei, Taiwan, October 13, 2020 — Steminent Biotherapeutics Inc. (President & CEO; Dr. Ling-Mei Wang) and SCM Lifescience Co., Ltd. (KOSDAQ: 298060, hereinafter SCM Lifescience, CEO: BG Rhee) today announced they have signed an exclusive license agreement for clinical development and commercialization of Steminent’s allogeneic cell therapy candidate; Stemchymal® for the treatment of Polyglutamine Spinocerebellar Ataxia (PolyQ SCAs) in South Korea. [Read more…]
Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy
Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, announced a collaboration to develop a COVID-19 treatment leveraging newborn stem cells. CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. [Read more…]
TreeFrog Therapeutics and Invetech Expand Partnership to Transition High-throughput Stem Cell Encapsulation Technology to GMP System for Commercial-scale Cell Therapy Manufacturing
-
TreeFrog Therapeutics and Invetech started their collaboration in 2019 to industrialize TreeFrog’s stem cell encapsulation technology to enable the mass production of hPSC-derived cell therapies in industrial bioreactors, with best-in-class cell quality and low production costs.
-
Invetech delivered a beta encapsulation system with a throughput of 1,000 stem cell capsules per second to TreeFrog Therapeutics in the second quarter of 2020.
-
The strategic partnership aims to develop a GMP-compliant encapsulation device by the end of 2022 to support TreeFrog Therapeutics’ in-house and partnered cell therapy programs.
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 144
- Next Page »